[go: up one dir, main page]

RU2010113966A - Применение меланотропинстимулирующего фактора в качестве терапевтического средства - Google Patents

Применение меланотропинстимулирующего фактора в качестве терапевтического средства Download PDF

Info

Publication number
RU2010113966A
RU2010113966A RU2010113966/15A RU2010113966A RU2010113966A RU 2010113966 A RU2010113966 A RU 2010113966A RU 2010113966/15 A RU2010113966/15 A RU 2010113966/15A RU 2010113966 A RU2010113966 A RU 2010113966A RU 2010113966 A RU2010113966 A RU 2010113966A
Authority
RU
Russia
Prior art keywords
diseases
disease
pharmaceutical composition
lys
peptide
Prior art date
Application number
RU2010113966/15A
Other languages
English (en)
Inventor
Дориан БЕВЕК (DE)
Дориан БЕВЕК
Фабио КАВАЛЛИ (CH)
Фабио КАВАЛЛИ
Вера КАВАЛЛИ (CH)
Вера КАВАЛЛИ
Геральд БАХЕР (DE)
Геральд БАХЕР
Original Assignee
Мондобайотек Лабораториз Аг (Li)
Мондобайотек Лабораториз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мондобайотек Лабораториз Аг (Li), Мондобайотек Лабораториз Аг filed Critical Мондобайотек Лабораториз Аг (Li)
Publication of RU2010113966A publication Critical patent/RU2010113966A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)

Abstract

1. Применение пептида Lys-Lys-Gly-Glu-OH для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из шока и повреждения ткани, синдрома повышения проницаемости сосудов, острого респираторного дистресс-синдрома, некроза желудочно-кишечного тракта, острого некроза почечных канальцев, кровоизлияния в надпочечниках, анорексии, гепатоспленомегалии, субэндокардиального воспаления, резистентности к инсулину, легочной гипертензии, саркоидоза, фиброза легких и/или COPD. ! 3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава. ! 5. Фармацевтическая композиция, содержащая пептид Lys-Lys-Gly-Glu-OH совместно с, по меньшей мере, одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем. ! 6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора. ! 7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции. ! 8. Фармацевтическая компо�

Claims (9)

1. Применение пептида Lys-Lys-Gly-Glu-OH для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
2. Применение пептида по п.1, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из шока и повреждения ткани, синдрома повышения проницаемости сосудов, острого респираторного дистресс-синдрома, некроза желудочно-кишечного тракта, острого некроза почечных канальцев, кровоизлияния в надпочечниках, анорексии, гепатоспленомегалии, субэндокардиального воспаления, резистентности к инсулину, легочной гипертензии, саркоидоза, фиброза легких и/или COPD.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Lys-Lys-Gly-Glu-OH совместно с, по меньшей мере, одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезней обмена веществ.
RU2010113966/15A 2007-09-11 2008-09-09 Применение меланотропинстимулирующего фактора в качестве терапевтического средства RU2010113966A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07017748 2007-09-11
EP07017748.0 2007-09-11

Publications (1)

Publication Number Publication Date
RU2010113966A true RU2010113966A (ru) 2011-10-20

Family

ID=40225088

Family Applications (8)

Application Number Title Priority Date Filing Date
RU2010113966/15A RU2010113966A (ru) 2007-09-11 2008-09-09 Применение меланотропинстимулирующего фактора в качестве терапевтического средства
RU2010114000/15A RU2010114000A (ru) 2007-09-11 2008-09-09 Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства
RU2010114027/15A RU2010114027A (ru) 2007-09-11 2008-09-09 Большой гастрин i в качестве терапевтического средства
RU2010113995/15A RU2010113995A (ru) 2007-09-11 2008-09-09 Применение ацетил-(ala10,11)-rantes(1-14) и/или кальцитонина в качестве антиангиогенных средств
RU2010114047/15A RU2010114047A (ru) 2007-09-11 2008-09-09 Применение нейропептида af человека в качестве терапевтического средства
RU2010113981/15A RU2010113981A (ru) 2007-09-11 2008-09-09 Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств
RU2010113977/15A RU2010113977A (ru) 2007-09-11 2008-09-09 Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010114025/15A RU2010114025A (ru) 2007-09-11 2008-09-09 ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА

Family Applications After (7)

Application Number Title Priority Date Filing Date
RU2010114000/15A RU2010114000A (ru) 2007-09-11 2008-09-09 Применение нейропептида sf индивидуально или в сочетании с glp-2 в качестве терапевтического средства
RU2010114027/15A RU2010114027A (ru) 2007-09-11 2008-09-09 Большой гастрин i в качестве терапевтического средства
RU2010113995/15A RU2010113995A (ru) 2007-09-11 2008-09-09 Применение ацетил-(ala10,11)-rantes(1-14) и/или кальцитонина в качестве антиангиогенных средств
RU2010114047/15A RU2010114047A (ru) 2007-09-11 2008-09-09 Применение нейропептида af человека в качестве терапевтического средства
RU2010113981/15A RU2010113981A (ru) 2007-09-11 2008-09-09 Применение гексапептидного антагониста рецептора тромбоцитарного фибриногена и альфа-эндорфина в качестве терапевтических средств
RU2010113977/15A RU2010113977A (ru) 2007-09-11 2008-09-09 Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010114025/15A RU2010114025A (ru) 2007-09-11 2008-09-09 ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА

Country Status (8)

Country Link
US (8) US20100197608A1 (ru)
EP (8) EP2205262A2 (ru)
JP (8) JP2010538997A (ru)
KR (8) KR20100058549A (ru)
AU (8) AU2008303811A1 (ru)
CA (8) CA2698775A1 (ru)
RU (8) RU2010113966A (ru)
WO (20) WO2009039974A2 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5647972B2 (ja) 2008-04-08 2015-01-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 環状ペプチドを含む組成物および使用方法
BR112012012862A2 (pt) * 2009-12-10 2016-08-16 Merck Patent Gmbh composição farmacêutica compreendendo oligopeptídeos
EP2560969B1 (en) * 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
EP2717854B1 (en) 2011-06-09 2019-01-16 Merck Patent GmbH Treatment of cancers and metastases with suspensions of cilengitide in carrier
CA3123992C (en) * 2011-09-29 2024-06-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
US9670259B2 (en) * 2013-03-14 2017-06-06 University Of Rochester Method of inhibiting angiogenesis using inhibitors of G-protein-coupled receptor kinase interacting protein-1 (GIT1)
EP2941091B1 (en) 2014-04-30 2019-04-24 Electrolux Appliances Aktiebolag Hob with free configurable heating array and touchscreen control, method for operating a hob with free configurable heating array and touchscreen control and computer program product
RU2577135C2 (ru) * 2014-07-01 2016-03-10 Диамондзлите Лимитед Способ лечения пациентов с онкологическими заболеваниями кожи при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный, плоскоклеточный рак (варианты)
CN104888198A (zh) * 2015-04-21 2015-09-09 徐志强 降钙素在制造延缓脑老化药物的新用途
WO2017019496A1 (en) * 2015-07-24 2017-02-02 Berenson James Richard Gamma secretase modulators for the treatment of immune system dysfunction
BR112019017120A8 (pt) 2017-02-17 2023-05-02 Hutchinson Fred Cancer Res Terapias de combinação para tratamento de cânceres e distúrbios autoimunes relacionados a bcma
CN108395470B (zh) * 2018-01-10 2020-10-09 北京工业大学 具有抑制登革病毒复制作用的短肽及其应用
JP6709440B2 (ja) * 2018-06-08 2020-06-17 学校法人福岡大学 肥厚性瘢痕の形成抑制用組成物
CN111647043B (zh) * 2019-08-07 2022-03-22 中国农业大学 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽
JP7629693B2 (ja) 2020-04-28 2025-02-14 小林製薬株式会社 抗菌剤
AU2022376893A1 (en) * 2021-10-25 2024-04-18 Pharma Holdings As Modified tripeptides for use in the treatment of a non-enveloped virus infection
EP4631518A1 (en) * 2024-04-08 2025-10-15 The Boots Company plc Compositions for treating diseases of the airways
WO2025215349A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Hair growth restoration
EP4631517A1 (en) * 2024-04-08 2025-10-15 The Boots Company plc Skin wound treatment
CN120931663B (zh) * 2025-10-16 2025-12-05 吉林大学 一种肺通气-灌注显影区域图像融合方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097471A (en) * 1977-05-26 1978-06-27 American Home Products Corporation Polypeptides with morphine-like activity
DE3274798D1 (en) * 1981-10-05 1987-02-05 Nicholas P Plotnikoff Process for using endorphins as antitumour agents
JPS6023086B2 (ja) * 1982-09-04 1985-06-05 工業技術院長 アンジオテンシン転換酵素阻害剤
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JPS62270533A (ja) * 1986-05-20 1987-11-24 Agency Of Ind Science & Technol 経口摂食物
CA1324954C (en) * 1988-03-10 1993-12-07 Erkki I. Ruoslahti Inhibition of cell migration with synthetic peptides
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH02240020A (ja) * 1989-01-26 1990-09-25 Childrens Medical Center Corp:The 外科的切除後の腫瘍再発阻止剤
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5256396A (en) 1990-01-24 1993-10-26 Colgate-Palmolive Company Topical composition
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
JP2745351B2 (ja) * 1991-02-14 1998-04-28 富士写真フイルム株式会社 ペプチド誘導体及びその用途
DE69128283T2 (de) 1991-08-12 1998-03-19 Nestle Sa Nahrungsmittelzusammensetzung
AU3064892A (en) * 1991-11-07 1993-06-07 University Of Southern California Compositions and methods for preventing adhesion formation
JP2918746B2 (ja) * 1991-12-18 1999-07-12 富士写真フイルム株式会社 ペプチド誘導体およびその用途
MX9301789A (es) * 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
ES2168312T3 (es) * 1993-09-24 2002-06-16 Univ Southern California Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.
JP3581174B2 (ja) * 1993-09-30 2004-10-27 新日本製鐵株式会社 新規ペプチド並びにそれを用いた血小板凝集抑制剤、体外循環用血液凝固抑制剤及び輸血用血小板製剤保護剤
EP0721468B1 (en) * 1993-09-30 2001-05-30 Nippon Steel Corporation Platelet aggregation inhibitory peptides
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
PL179910B1 (pl) 1994-05-06 2000-11-30 Pfizer Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
DE19529909C2 (de) * 1995-08-15 1998-04-09 Fresenius Ag Wässrige Spüllösung
US5691314A (en) * 1996-03-18 1997-11-25 The Medical College Of Hampton Roads Adjunctive therapy
AU3499997A (en) * 1996-06-24 1998-01-14 Rockefeller University, The Method of using ligands of the kappa opioid receptor
TW360501B (en) 1996-06-27 1999-06-11 Nestle Sa Dietetically balanced milk product
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
DE69608801T2 (de) 1996-09-24 2000-10-12 Societe Des Produits Nestle S.A., Vevey Milchaustauschprodukt und Verfahren zu dessen Herstellung
GB9704174D0 (en) * 1997-02-28 1997-04-16 Univ Birmingham Agent for medical treatment
AU8333998A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S New use of nociceptin
IT1299134B1 (it) * 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
US6239109B1 (en) * 1998-02-09 2001-05-29 University Of Southern California Method of promoting erythropoiesis
US5958874A (en) * 1998-02-18 1999-09-28 The Research Foundation Of State University Of New York Recombinant fibronectin-based extracellular matrix for wound healing
ES2226466T3 (es) 1998-11-24 2005-03-16 Societe Des Produits Nestle S.A. Procedimiento de preparacion de una composicion proteinica y de una formula infantil que la contiene.
WO2001017958A2 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Neuropeptide sf receptor assays, compounds and therapeutic methods
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
DE60227507D1 (de) * 2001-04-30 2008-08-21 Aeterna Zentaris Gmbh Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit
US8633150B2 (en) * 2001-05-16 2014-01-21 Tni Biotech, Inc. Methods for inducing sustained immune response
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
EP1314357B1 (en) 2001-11-23 2007-05-23 Société des Produits Nestlé S.A. Process for the preparation of milk powders and concentrated milk products
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
GB0208499D0 (en) * 2002-04-12 2002-05-22 Microscience Ltd Streptococcal genes
AU2003276828A1 (en) * 2002-05-10 2004-03-11 Children's Medical Center Corporation Minicell display and products therefrom
AU2003285200A1 (en) * 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US20050282747A1 (en) * 2003-10-01 2005-12-22 The Research Foundation Of State University Of New York At Stony Brook Methods and compositions for wound healing
CA2511711A1 (en) * 2004-07-08 2006-01-08 Les Laboratoires Omega Ltee Liquid pharmaceutical formulations of octreotide, manufacturing process and container for the same
US7704955B2 (en) * 2004-11-24 2010-04-27 Neopro Pain, Inc. Methods and compositions for modulating conditions in both mammals and plants
US7550150B2 (en) * 2005-03-15 2009-06-23 Barros Research Institute Methods of treating or preventing a disease, disorder or condition associated with a viral infection
US20090011987A1 (en) * 2005-05-19 2009-01-08 Novo Nordisk A/S Use of Glp-2 for the Treatment of Ischemia-Reperfusion Injury
US20070093420A1 (en) * 2005-08-26 2007-04-26 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
CA2625150A1 (en) * 2005-10-07 2007-04-19 Waratah Pharmaceuticals, Inc. Combined use of dpp-iv inhibitors and gastrin compounds
WO2007095737A1 (en) * 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
WO2007100335A1 (en) * 2006-03-03 2007-09-07 The Mclean Hospital Corporation Methods for the treatment of mood disorders
DE502007001190D1 (de) 2006-03-10 2009-09-10 Laboswiss Ag Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
DK2146733T3 (da) * 2007-03-14 2021-01-11 Arch Biosurgery Inc Treatment of leaky or damaged tight junctions and enhancing extracellular matrix

Also Published As

Publication number Publication date
WO2009033781A2 (en) 2009-03-19
AU2008303811A1 (en) 2009-04-02
EP2205262A2 (en) 2010-07-14
EP2185180A1 (en) 2010-05-19
JP2010538997A (ja) 2010-12-16
WO2009040025A3 (en) 2009-05-22
EP2187908A1 (en) 2010-05-26
WO2009039995A1 (en) 2009-04-02
RU2010114000A (ru) 2011-10-20
EP2187923A2 (en) 2010-05-26
KR20100059855A (ko) 2010-06-04
CA2699054A1 (en) 2009-04-02
CA2698978A1 (en) 2009-03-19
WO2009039974A2 (en) 2009-04-02
WO2009049742A2 (en) 2009-04-23
KR20100058549A (ko) 2010-06-03
WO2009033765A2 (en) 2009-03-19
WO2009039988A3 (en) 2009-09-03
KR20100057053A (ko) 2010-05-28
WO2009049742A3 (en) 2009-09-03
RU2010113995A (ru) 2011-10-20
WO2009039974A3 (en) 2009-07-16
JP2010539023A (ja) 2010-12-16
WO2009039988A2 (en) 2009-04-02
WO2009033681A2 (en) 2009-03-19
US20100210532A1 (en) 2010-08-19
WO2009040071A2 (en) 2009-04-02
JP2010539034A (ja) 2010-12-16
AU2008303951A1 (en) 2009-04-02
WO2009033730A2 (en) 2009-03-19
WO2009033725A1 (en) 2009-03-19
WO2009033801A3 (en) 2009-09-03
CA2699177A1 (en) 2009-04-02
AU2008303950A1 (en) 2009-04-02
WO2009040049A3 (en) 2009-09-24
KR20100057058A (ko) 2010-05-28
WO2009033765A3 (en) 2009-08-20
US20100197601A1 (en) 2010-08-05
EP2187906A2 (en) 2010-05-26
AU2008303889A1 (en) 2009-04-02
US20100197608A1 (en) 2010-08-05
KR20100061678A (ko) 2010-06-08
WO2009033781A3 (en) 2009-10-29
WO2009033730A3 (en) 2009-10-01
WO2009040049A2 (en) 2009-04-02
KR20100061483A (ko) 2010-06-07
WO2009033801A2 (en) 2009-03-19
US20100190716A1 (en) 2010-07-29
US20100184704A1 (en) 2010-07-22
KR20100058553A (ko) 2010-06-03
WO2009040021A2 (en) 2009-04-02
AU2008303957A1 (en) 2009-04-02
AU2008306264A1 (en) 2009-04-09
EP2187952A1 (en) 2010-05-26
WO2009040025A2 (en) 2009-04-02
RU2010113981A (ru) 2011-10-20
WO2009039989A1 (en) 2009-04-02
JP2010539040A (ja) 2010-12-16
WO2009040071A3 (en) 2009-12-17
WO2009043441A1 (en) 2009-04-09
US20100204115A1 (en) 2010-08-12
WO2009033803A3 (en) 2009-05-14
JP2010539004A (ja) 2010-12-16
CA2699075A1 (en) 2009-04-23
WO2009033681A3 (en) 2009-09-24
CA2699049A1 (en) 2009-04-02
AU2008297899A1 (en) 2009-03-19
CA2698775A1 (en) 2009-04-02
WO2009043459A1 (en) 2009-04-09
WO2009046857A1 (en) 2009-04-16
JP2010539044A (ja) 2010-12-16
RU2010114047A (ru) 2011-10-20
CA2699107A1 (en) 2009-04-09
EP2187925A1 (en) 2010-05-26
US20100190711A1 (en) 2010-07-29
RU2010114025A (ru) 2011-10-20
KR20100056511A (ko) 2010-05-27
AU2008314244A1 (en) 2009-04-23
EP2187917A2 (en) 2010-05-26
RU2010114027A (ru) 2011-10-20
WO2009040021A3 (en) 2009-06-25
RU2010113977A (ru) 2011-10-20
US20100204130A1 (en) 2010-08-12
JP2010538998A (ja) 2010-12-16
WO2009033659A1 (en) 2009-03-19
JP5385282B2 (ja) 2014-01-08
JP2010539019A (ja) 2010-12-16
WO2009033803A2 (en) 2009-03-19
CA2699244A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
RU2010113966A (ru) Применение меланотропинстимулирующего фактора в качестве терапевтического средства
RU2010113986A (ru) Применение пептида в качестве терапевтического средства
RU2010114033A (ru) Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv
RU2010114013A (ru) Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств
RU2010114030A (ru) Применение пептида в качестве терапевтического средства
RU2010114002A (ru) Применение фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa
RU2010114051A (ru) Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств
RU2010114045A (ru) Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств
RU2010113979A (ru) Применение bubuc и необязательно eaa-marti (26-35) в качестве терапевтического средства для лечения инфекций hcmv
RU2010113974A (ru) Применение противовоспалительного пептида-1 в качестве терапевтического средства
RU2010113999A (ru) Применение секретина и необязательно уродилатина в качестве терапевтических средств
RU2010114052A (ru) Применение пептида в качестве терапевтического средства
RU2010113992A (ru) Применение урокортина и кортиколиберина в качестве терапевтических средств
RU2010114007A (ru) Применение комбинации пептидов cart в качестве терапевтического средства
RU2010114049A (ru) Cgrp в качестве терапевтического средства
RU2010114017A (ru) Терапевтическое применение натрийуретического пептида в-типа и гормона роста человека 1-43
RU2010114023A (ru) ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010113984A (ru) Применение врр-в в качестве терапевтического средства
RU2010114035A (ru) Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства
RU2010114005A (ru) Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства
RU2010114037A (ru) Применение белка полосы 3 и расар-27 в качестве терапевтического средства

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110912